Stritinib Imatinib mesylate 100mg Tablet

Trade Name: Stritinib

Manufacturer: Mylan Pharmaceuticals Pvt Ltd

Presentation: Tablet

Strength: 100mg

What is Stritinib Imatinib mesylate 100mg Tablet?

Stritinib Imatinib mesylate 100mg Tablet belongs to the tyrosine kinase inhibitors class of medicines. It is used to treat blood cancers (persistent myeloid leukaemia and acute lymphocytic leukaemia) as well as gastrointestinal stromal cancer.

How long can I take imatinib?

Although the optimal treatment period is uncertain, imatinib should normally be continued for 6–9 months, after which additional tumour shrinking is usually minimal.

What are the side effects of imatinib?

  • More common
  • Pain, cramping, burning, or soreness in the abdomen or stomach.
  • bleeding from the wound after surgery.
  • bleeding problems.
  • Face, hands, lower legs, or feet bloating or edoema
  • blood in the urine.
  • bloody eye.
  • bloody nose.
  • blue lips and fingernails.
  • For more details Click Here.

Can imatinib cause bleeding?

GI Bleed and Tear: This medication can cause bleeding or a tear in the intestinal wall. Signs of these problems include: unexpected bleeding, blood in the stool or black stools, coughing up blood, vomiting blood, vomit that looks like coffee grounds, fever, severe pain in the abdomen or new abdominal swelling.

Can imatinib cause anemia?

Introduction. With imatinib therapy for newly diagnosed chronic myeloid leukaemia (CML) in the chronic phase, the incidence of grade 3–4 anaemia was reported to be 3%. (CP). However, there are limited data on the causes of anaemia and how it develops following long-term treatment.

Does imatinib affect sleep?

Imatinib and other tyrosine kinase inhibitors (TKIs) for CML had to be taken every day for the rest of one’s life until recently, and the medications might cause exhaustion, depression, disrupted sleep, diarrhoea, and other side effects.

Can imatinib cause depression?

Prescribing Information Lists Depression as Adverse Effect

In a clinical trial of imatinib, depression (all degrees) occurred in 14.9 per cent of newly diagnosed chronic myeloid leukaemia patients, whereas grade 3/4 depression occurred in 0.5 per cent of patients.

If you are looking for another product or brand click here.